We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Arachidonic Acid Stimulates Cancer Growth

By Biotechdaily staff writers
Posted on 16 Feb 2006
Researchers have found that arachidonic acid, an omega-6 fatty acid, stimulated the growth of tumor cells by activating the metabolic pathway leading to prostaglandin synthesis and translocation to the nucleus of nuclear factor-kappaB (NF-kappaB).

Investigators at the San Francisco Veterans Administration Medical Center (CA, USA) added arachidonic acid to human prostate tumor cells growing in tissue culture. More...
They found that this prompted the cells to grow at a rate nearly double that of control cells that did not receive arachidonic acid.

Analysis using gene chip technology showed that arachidonic acid induced 11 genes that were regulated by NF-kappaB. Within five minutes of addition of arachidonic acid prostaglandin E2 (PGE2) synthesis was increased, and analysis of upstream signal transduction showed that phosphatidylinositol 3-kinase (PI3K) was significantly activated. These events were followed by activation of Akt at 30 minutes, when a significant three-fold increase in translocation of NF-kappaB to the nucleus was seen. Interruption of the pathway by treatment with either a COX-2 inhibitor or with a PI3K inhibitor reversed the stimulatory effect of arachidonic acid. These findings were published in the February 1, 2006, issue of Cancer Research.

Senior author Dr. Mille Hughes-Fulford, director of the Laboratory of Cell Growth at the San Francisco Veterans Administration Medical Center, said, "Investigating the reasons for this rapid growth, we discovered that the omega-6 was turning on a dozen inflammatory genes that are known to be important in cancer. We then asked what was turning on those genes, and found that omega-6 fatty acids actually turn on a signal pathway called PI3-kinase that is known to be a key player in cancer. I am not a physician, and do not tell people how to eat, but in my own home I use only canola oil and olive oil. We do not eat deep-fried foods.”



Related Links:
San Francisco Veterans Administration Medical Center

Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Clinical Informatics Platform
CLARION™
New
HPV Molecular Test
BD Onclarity HPV Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.